;

42.66 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 11:09:42 AM)
Exchange open, closes in 4 hours 50 minutes
3.00 USD (3.00%)
3.00 USD (3.00%)
-13.53 USD (-13.53%)
-19.20 USD (-19.20%)
55.17 USD (55.17%)
177.70 USD (177.70%)
337.49 USD (337.49%)

About Merus NV

Market Capitalization 2.87B

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Headquarters (address)

Uppsalalaan 17

Utrecht 3584 CT

Netherlands

Phone31 30 253 8800
Websitehttps://www.merus.nl
Employees172
SectorHealthcare
IndustryBiotechnology
TickerMRUS
ExchangeNASDAQ Stock Exchange
CurrencyUSD
52 week range27.11 - 61.61
Market Capitalization2.87B
P/E trailing-13.95
P/E forward-10.73
Price/Sale79.74
Price/Book4.07
Beta1.12
EPS-4.03
EPS Netherlands (ID:23, base:88) 1.55

CleverShares.com|
2024 ©

1.0.9119.29486